Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells
作者:Cecília P. Popolin、João P. B. Reis、Amanda B. Becceneri、Angélica E. Graminha、Márcio A. P. Almeida、Rodrigo S. Corrêa、Legna A. Colina-Vegas、Javier Ellena、Alzir A. Batista、Márcia R. Cominetti
DOI:10.1371/journal.pone.0183275
日期:——
Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype. The high rate of metastasis associated to the fact that these cells frequently display multidrug resistance, make the treatment of metastatic disease difficult. Development of antitumor metal-based drugs was started with the discovery of cisplatin, however, the severe side effects represent a limitation for its clinical use. Ruthenium (Ru) complexes with different ligands have been successfully studied as prospective antitumor drugs. In this work, we demonstrated the activity of a series of biphosphine bipyridine Ru complexes (1) [Ru(SO4)(dppb)(bipy)], (2) [Ru(CO3)(dppb)(bipy)], (3) [Ru(C2O4)(dppb)(bipy)] and (4) [Ru(CH3CO2)(dppb)(bipy)]PF6 [where dppb = 1,4-bis(diphenylphosphino)butane and bipy = 2,2’-bipyridine], on proliferation of TNBC (MDA-MB-231), estrogen-dependent breast tumor cells (MCF-7) and a non-tumor breast cell line (MCF-10A). Complex (4) was most effective among the complexes and was selected to be further investigated on effects on tumor cell adhesion, migration, invasion and in apoptosis. Moreover, DNA and HSA binding properties of this complex were also investigated. Results show that complex (4) was more efficient inhibiting proliferation of MDA-MB-231 cells over non-tumor cells. In addition, complex (4) was able to inhibit MDA-MB231 cells adhesion, migration and invasion and to induce apoptosis and inhibit MMP-9 secretion in TNBC cells. Complex (4) should be further investigated in vivo in order to stablish its potential to improve breast cancer treatment.
三阴性乳腺癌(TNBC)是一种侵袭性很强的乳腺癌亚型。由于这些细胞经常表现出多药耐药性,因此转移率很高,给转移性疾病的治疗带来了困难。抗肿瘤金属药物的开发始于顺铂的发现,但其严重的副作用限制了其临床应用。人们已经成功地研究了不同配体的钌(Ru)配合物,将其作为未来的抗肿瘤药物。在这项工作中,我们展示了一系列双膦双吡啶 Ru 配合物(1)[Ru(SO4)(dppb)(bipy)]、(2)[Ru(CO3)(dppb)(bipy)]、(3)[Ru(C2O4)(dppb)(bipy)]和(4)[Ru(CH3CO2)(dppb)(bipy)]PF6 [其中 dppb = 1、4-双(二苯基膦)丁烷和 bipy = 2,2'- 联吡啶],对 TNBC(MDA-MB-231)、雌激素依赖性乳腺肿瘤细胞(MCF-7)和非肿瘤乳腺细胞系(MCF-10A)的增殖均有效。复合物(4)在这些复合物中最为有效,因此被选中进一步研究其对肿瘤细胞粘附、迁移、侵袭和凋亡的影响。此外,还研究了该复合物的 DNA 和 HSA 结合特性。结果表明,复合物(4)对 MDA-MB-231 细胞增殖的抑制作用强于非肿瘤细胞。此外,复合物(4)还能抑制 MDA-MB231 细胞的粘附、迁移和侵袭,并能诱导 TNBC 细胞凋亡和抑制 MMP-9 的分泌。复合物(4)应在体内进一步研究,以确定其改善乳腺癌治疗的潜力。